Astrazeneca annual return on assets (roa)
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Return on Assets (ROA) Growth & History (AZN)
Astrazeneca's return on assets (roa) was 9.38% for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual return on assets (roa) history
| Fiscal year | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 9.38% | +2.52 pp |
| 2024 | 2024-12-31 | 6.86% | +0.83 pp |
| 2023 | 2023-12-31 | 6.03% | +2.77 pp |
| 2022 | 2022-12-31 | 3.26% | +3.13 pp |
| 2021 | 2021-12-31 | 0.13% | −4.77 pp |
| 2020 | 2020-12-31 | 4.91% | +2.90 pp |
| 2019 | 2019-12-31 | 2.01% | −1.30 pp |
| 2018 | 2018-12-31 | 3.31% | −1.25 pp |
| 2017 | 2017-12-31 | 4.56% | −1.00 pp |
| 2016 | 2016-12-31 | 5.56% | — |
Astrazeneca quarterly return on assets (roa)
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 9.15% | — |
| Q1 2026 | 2026-03-31 | 9.53% | — |
Astrazeneca return on assets (roa) trends
Over the last five fiscal years, Astrazeneca's return on assets (roa) increased from 4.91% to 9.38%, a change of +4.47 percentage points. The latest reported quarter, Q2 2026, shows 9.15%.
About the metric
What return on assets means
Return on assets measures profit relative to the assets used to generate it. It can help compare operating efficiency over time, although normal ROA differs substantially between asset-light and asset-intensive industries.
Calculation and source
How return on assets is calculated
TickerStat calculates annual ROA as reported net income divided by average total assets. Quarterly observations use trailing-12-month net income and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...